Experienced leader of large national and international randomized clinical trials in anaesthesiology. Founder of WARD 24/7 (Wireless Assessment of Respiratory and circulatory Distress) - developing a clinical support system for continuous wireless monitoring of vital signs.

Postoperative cardiopulmonary complications; remote automated continuous wireless monitoring; large multicentre randomized clinical trials; anaesthesiology and perioperative care; oxygen therapy; surgical site infection.

Clinical research in all sections of the anaesthesiological specialty (anaesthesia, intensive care, pain medicine and prehospital emergency care), and especially in the area of identification and prevention of cardiopulmonary complications. 

• WARD-project (ward247.org)
• Oxygen and postoperative complications
• Prevention of myocardial injury after non-cardiac surgery (MINS)
• POISE-3 trial (clinicaltrials.gov/ct2/show/NCT03505723)
• SphenoPalatine Ganglion block for headache relief
• Acute toxicology in ICU
• Trials in septic shock, including endotheliopathy

My departm

Co-founder of a start-up company, WARD247 ApS, with the aim of pursuing the regulatory and commercial activities of the WARD-project (Wireless Assessment of Respiratory and circulatory Distress, a project developing a clinical support system for continuous wireless monitoring of vital signs). WARD247 ApS has obtained license agreement for any WARD-project software and patents. One patent has been filed: “Wireless Assessment of Respiratory and circulatory Distress (WARD) – Clinical Support System (CSS) – an automated clinical support system to improve patient safety and outcomes”. 

In addition: direct and indirect departmental research funding from Boehringer Ingelheim and Merck, Sharp & Dohme as well as lecture fees from Radiometer.

ent receives direct and indirect research funding from Boehringer Ingenheim and Ferring Pharmaceuticals.